Analyzing InMode (INMD) and The Competition

InMode (NASDAQ:INMD) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare InMode to similar businesses based on the strength of its earnings, risk, dividends, analyst recommendations, institutional ownership, profitability and valuation.

Earnings & Valuation

This table compares InMode and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
InMode	$374.62 million	$93.83 million	10.85
InMode Competitors	$1.90 billion	$135.83 million	5.88

InMode’s competitors have higher revenue and earnings than InMode. InMode is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares InMode and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMode	20.69%	11.99%	10.60%
InMode Competitors	-304.20%	-315.07%	-22.11%

Risk and Volatility

InMode has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, InMode’s competitors have a beta of 2.57, suggesting that their average stock price is 157% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for InMode and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1	3	1	0	2.00
InMode Competitors	4291	10579	18364	831	2.46

InMode presently has a consensus price target of $16.33, suggesting a potential upside of 22.44%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.72%. Given InMode’s higher possible upside, research analysts plainly believe InMode is more favorable than its competitors.

Insider & Institutional Ownership

68.0% of InMode shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 6.9% of InMode shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

InMode competitors beat InMode on 7 of the 13 factors compared.

InMode Company Profile

InMode Ltd. is an Israel-based medical technology company that develops energy-based systems for minimally invasive aesthetic and medical procedures. Its technologies use radiofrequency energy to support treatments such as body contouring, skin tightening and facial rejuvenation, as well as certain women’s health applications. The company’s product portfolio includes platforms and handpieces such as BodyTite and FaceTite for body and facial contouring, and Morpheus8 for fractional radiofrequency skin treatments.